-
Security Type
-
SAFE
-
Categories
-
Technology
-
Min Investment
-
$100
-
Offering Date
-
September 15, 2021
-
Target Raise
-
$50.00K
Company Description
First-in-class AI-powered app to control ASTHMA Cough detection and warning system to prevent asthma crisis.
Key Deal Facts
US National Academy of Medicine Grand Award 2020 Winner for the most disruptive technologies.
Rapid growth: 1,000 users in the first month after launch despite close to no marketing efforts.
Target Audience: patients with cough-related diseases such as COVID-19, ASTMA, FLU, COPD, etc.
Market size: COVID-19 (220M people), FLU (800M), ASTHMA (400M), COPD (220M).
Scaling potential: up to 30% of all health-related costs are related to respiratory diseases.
96% Cough detection Accuracy validated with independent healthcare experts.
Use of Proceeds
- Marketing
- IT, Team and Overhead
- Research
Management Team / Advisory Board Bios
Igor Dzhekiev, CEO & Founder
US National Academy of Medicine 2020 Award Winner for the most disruptive technologies that can transform Healthcare. Backed with a Grant by US NAM.
Daria Venkova, Chief Investment Officer
Award winning entrepreneur in healthcare, deep-tech and life sciences with a background in business development and biotechnology. Former executive of a platform diagnostic company. CEO and head of business strategy at Purley A&D Consulting.
Santiago C. Arce, Chief Respiratory Officer
Consultant to the Argentine Ministry of Health Head of pulmonology lab, University of Buenos Aires.